Puma Biotechnology Inc. buy Global_Player
Start price
15.11.24
/
50%
€2.28
Target price
15.11.25
-
Performance (%)
13.44%
End price
18.11.24
€2.58
Summary
This prediction ended on 18.11.24 with a price of €2.58. The BUY prediction by Global_Player finished with a performance of 13.44%. Global_Player has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Puma Biotechnology Inc. | 12.241% | 12.241% | 79.038% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% |
According to Global_Player what are the pros and cons of Puma Biotechnology Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by Global_Player for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Buy Puma Biotechnology Inc.
In the thread Trading Puma Biotechnology Inc.
Stopped prediction by Global_Player for Puma Biotechnology Inc.
Puma Biotechnology Inc.
Start price
Target price
Perf. (%)
€6.60
10.10.19
10.10.19
€10.00
14.10.19
14.10.19
-4.64%
14.10.19
14.10.19
